IP Library Granted Patent US 7,820,824
Granted Patent B2
US 7,820,824 · App. 11/675,037 · Granted Oct 26, 2010

Modified carbocyanine dyes and their conjugates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,824
App. No.
11/675,037
Granted
Oct 26, 2010
Kind
B2
Abstract

Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.

Claims (54)

1. A method of staining a biological sample, comprising:

combining a dye solution comprising a compound having the formula:

and its salts, wherein

R 3 comprises an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazide, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, a thiol group, a protein, a peptide, an amino acid, a dextran, a hormone, a lectin, a lipopolysaccharide, a biological cell, a nucleotide, an oligonucleotide, or a small-molecule drug;

R 4 is a C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium; or

R 3 and R 4 taken in combination complete a five- or six-membered saturated or unsaturated ring that is substituted by a group comprising an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazide, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, a thiol group, a protein, a peptide, an amino acid, a dextran, a hormone, a lectin, a lipopolysaccharide, a biological cell, a nucleotide, an oligonucleotide, or a small-molecule drug;

R 2 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium;

R 6 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 7 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 8 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 9 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl; or

a member independently selected from

R 6 in combination with R 7 ;

R 7 in combination with R 8 ; and

R 8 in combination with R 9 ;

together with the atoms to which they are joined, form an aromatic ring comprising —CH or —CR 1 wherein R 1 is amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, wherein each alkyl portion of which is optionally substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

n is 0, 1, 2 or 3;

W represents the atoms necessary to form one to two fused aromatic rings having 5 or 6 atoms in each ring, wherein said W atoms are selected from the group consisting of —CH, —C, —CR 1′ , and —N(R 12 ) β ′, where β′ is 0 or 1, but no more than one of said atoms in W is —N(R 12 ) β ′, and each R 1′ is amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, wherein each alkyl portion of which is optionally substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxy;

δ is 0 or 1, and δ+β′=1;

R 12 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium;

R 13 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by substituents selected from the group consisting of F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, and C 3 -C 18 trialkylammonium;

R 14 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by substituents selected from the group consisting of F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, and C 3 -C 18 trialkylammonium,

or R 13 and R 14 taken in combination complete a five- or six-membered saturated or unsaturated ring that is optionally substituted;

with a biological sample in a concentration sufficient to yield a detectable optical response under desired conditions.

2. The method according to claim 1 , wherein R 3 comprises a protein, a peptide, an amino acid, a dextran, a hormone, a lectin, a lipopolysaccharide, a biological cell, a nucleotide, an oligonucleotide, or a small-molecule drug.

3. The method according to claim 1 , wherein R 3 comprises an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazide, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, or a thiol group.

4. The method according to claim 1 , wherein R 3 comprises an antibody or fragment thereof, a blood component protein, a blood vessel proliferation inhibition factor, an enzyme, an enzyme inhibitor, a hormone, an IgG-binding protein, a fluorescent protein, a growth factor, a metal-binding protein, a microorganism or portion thereof, a neuropeptide, a peptide toxin, a phospholipid-binding protein, or a structural protein.

5. The method according to claim 1 , wherein the sample comprises cells, proteins, or nucleic acid polymers.

6. The method according to claim 1 , wherein the sample is contained in or on a solid or semi-solid matrix that is a membrane, an electrophoretic gel, silicon chip, a glass slide, a microwell plate or a microfluidic chip.

7. A method for forming a dye-conjugate of a protein, peptide or a nucleic acid polymer, said method comprising:

combining a dye solution comprising a compound of the formula

and its salts, wherein

R 3 comprises an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazide, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, or a thiol group;

R 4 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium; or

R 3 and R 4 taken in combination complete a five- or six-membered saturated or unsaturated ring that is substituted by an acrylamide, an activated ester of a carboxylic acid, an acyl azide, an acyl nitrile, an aldehyde, an alkyl halide, an amine, an anhydride, an aniline, an aryl halide, an azide, an aziridine, a boronate, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, a hydrazide, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a phosphoramidite, a reactive platinum complex, a sulfonyl halide, or a thiol group;

R 2 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium;

R 6 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 7 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 8 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

R 9 is H, amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, each alkyl portion of which is optionally further substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl; or

a member independently selected from

R 6 in combination with R 7 ;

R 7 in combination with R 8 ; and

R 8 in combination with R 9 ;

together with the atoms to which they are joined, form an aromatic ring comprising —CH or —CR 1 wherein R 1 is amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, wherein each alkyl portion of which is optionally substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxyl;

n is 0, 1, 2 or 3;

W represents the atoms necessary to form one to two fused aromatic rings having 5 or 6 atoms in each ring, wherein said W atoms are selected from the group consisting of —CH, —C, —CR 1′ , and —N(R 12 ) β ′, where β′ is 0 or 1, but no more than one of said atoms in W is —N(R 12 ) β ′, and each R 1′ is amino, sulfo, trifluoromethyl, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, or C 2 -C 12 dialkylamino, wherein each alkyl portion of which is optionally substituted by substituents selected from the group consisting of carboxy, sulfo, amino, and hydroxy;

δ is 0 or 1, and δ+β′=1;

R 12 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, or C 3 -C 18 trialkylammonium;

R 13 is C 1 -C 22 alkyl armor C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by substituents selected from the group consisting of F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, and C 3 -C 18 trialkylammonium;

R 14 is C 1 -C 22 alkyl or C 7 -C 22 arylalkyl, each alkyl portion of which optionally incorporates up to six hetero atoms, selected from the group consisting of N, O and S, and each alkyl portion of which is optionally substituted one or more times by substituents selected from the group consisting of F, Cl, Br, I, hydroxy, carboxy, sulfo, phosphate, amino, sulfate, phosphonate, cyano, nitro, azido, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 2 -C 12 dialkylamino, and C 3 -C 18 trialkylammonium,

or R 13 and R 14 taken in combination complete a five- or six-membered saturated or unsaturated ring that is optionally substituted;

with a sample comprising a protein, peptide or a nucleic acid polymer whereby a dye conjugate is formed.

8. The method according to claim 7 , wherein R 3 comprises a carboxylic acid, an amine, an activated ester of a carboxylic acid, a halotriazine, a hydrazine, a maleimide, or a reactive platinum complex.

Assignments (3)
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2010
From: MOLECULAR PROBES, INC.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 024686/0321 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →